Kolon Life Science Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was KRW 27.26 million compared to KRW 27.55 million a year ago. Net loss was KRW 2,860.79 million compared to KRW 224.97 million a year ago. Basic loss per share from continuing operations was KRW 251 compared to KRW 20 a year ago. Basic loss per share was KRW 251 compared to KRW 20 a year ago.